Ex vivo culture of hematopoietic progenitor cells for autologous transplantation has generated world-wide interest, since it offers the prospect of using a limited cell number, and may allow more efficient gene transfer and passive elimination of contaminating tumor cells. In this study, we expanded bone marrow (BM) cells from 10 breast cancer patients to determine whether small BM aliquots can durably restore hematopoiesis, and whether thrombopoietin (TPO) improves hematopoietic reconstitution after myeloablative chemotherapy. We used the AastromReplicell System (ARS), performing a computer-controlled, stromal-based cell expansion process with frequent medium, cytokine and gas exchange. Studies on ex vivo expanded cells using cord blood (CB), peripheral blood (PB) and bone marrow (BM) cells have been widely undertaken, both in preclinical and clinical settings, since cultured cells are prime targets for gene therapy, allow implementation of purging techniques, and may enable the use of a limited cell number, such as for CB transplants or non-mobilizing patients.
be valuable in settings in which only small stem cell doses are available, eg when using cord blood transplants or in non-mobilizing patients. Bone Marrow Transplantation (2001) 27, 249-259. Keywords: ex vivo culture; autologous transplantation; STAMP V Studies on ex vivo expanded cells using cord blood (CB), peripheral blood (PB) and bone marrow (BM) cells have been widely undertaken, both in preclinical and clinical settings, since cultured cells are prime targets for gene therapy, allow implementation of purging techniques, and may enable the use of a limited cell number, such as for CB transplants or non-mobilizing patients. [1] [2] [3] [4] [5] [6] Preclinical experiments have shown that hematopoietic cells from different sources can be expanded with increase of total cells and CFU-GM, and preservation of severe-combined immunodeficiency (SCID) mice repopulating cells (SRC) and long-term culture-initiating cells (LTC-IC). [1] [2] [3] [4] [5] [6] [7] However, whether primitive stem cells, such as Lin − /CD34 + cells can be expanded is still a matter of debate. Multiple cytokines have proven beneficial for ex vivo culture, including stem cell factor (SCF), Flt-3, TPO, IL-6, IL-1, IL-3, and others. [8] [9] [10] [11] [12] In most preclinical and clinical studies CD34 + selected cells have been used, but perfusion bioreactors have proven capable of expanding non-enriched cells due to their ability to support high density cell populations. 5, [13] [14] [15] [16] Clinical trials with reinfusion of ex vivo generated cells have demonstrated hematopoietic engraftment, even after myeloablative chemotherapy. 6, 17 In some of these trials, a novel automated perfusion system has been utilized, where under GMP requirements cells generated ex vivo were given after high-dose therapy. 5, 6, 17 The initial US pilot study infused ex vivo cultured BM with unexpanded conventional BM, demonstrating no toxicity from the infused cells and potential benefits as measured by shortening of engraftment, reduced days of febrile neutropenia and hospital stay. 17 In addition, subsequent in vitro studies verified passive tumor cell purging when BM contaminated with tumor cells was cultured in this system. 18 On the basis of this and preliminary data from a phase II study, 6, 19 we conducted this analysis using ex vivo gener-ated BM after myeloablative chemotherapy in 10 advanced breast cancer patients, and compared these results to nonexpanded peripheral blood stem cell transplantations (PBSCT), the latter being routinely used in autologous transplants at our institution. Endpoints of the ARS culture included reliability of the system, cell, CFU and LTC-IC expansion and tumor cell depletion, as well as post transplant kinetics such as time to engraftment, transfusion requirements, days of fever, intravenous antibiotics and hospital discharge. In addition to this detailed analysis and a recently published study using ARS cells, 19 we determined the significance of non-G-CSF-mobilized BM for ARS culture and of TPO and irradiated PBSC addition for the transplant course.
Our results from this analysis demonstrate that small, non-G-CSF-mobilized BM aliquots allow hematopoietic reconstitution after myeloablative chemotherapy which was similar to non-expanded PBSCT, and that transplantation of TPO expanded ARS cells display clinical advantages. The ARS procedure can reduce the risk of tumor cell reinfusion in autotransplants, and may therefore be valuable for purging strategies, gene transfer and in settings in which only small stem cell doses are available.
Patients and methods

Selection of patients
Patients with stage II (with more than 10 involved axillary nodes) and III/IV breast cancer were eligible for high-dose chemotherapy. Stage IV disease patients were required to have chemotherapy responsive disease. For all patients, histologically normal bilateral BM aspirates and biopsies with a minimum cellularity of 30%, no comorbid illness, normal cardiac ejection fraction and interval of 4 weeks from previous chemotherapy or radiotherapy were required. Of 10 patients transplanted (median age 46 years; range, 34-59, median body weight 70 kg, range, 54-99), three had highrisk stage II, one stage III and six stage IV disease. Three out of the latter stage IV patients had histologically proven BM tumor involvement, however, none had bone scan abnormalities in their pelvic bones. Previous chemotherapy cycles were five (range, 0-7). This phase II study was carried out under the guidelines of the ethical committee of the University of Freiburg, and was approved by the Institutional Review Board. Informed consent was obtained from each patient. Data were analyzed as of 31 March 2000. The median follow-up was 457 days (range, 167-709).
Collection of PBSC
To obtain a back-up in case of delayed engraftment, a PBSC collection was performed after two cycles of PEC (paclitaxel 175 mg/m 2 , epirubicin 90 mg/m 2 and cyclophosphamide 600 mg/m 2 ) chemotherapy plus G-CSF (5 g/kg bw, Neupogen; Amgen) priming. These cryopreserved cells were to be infused with an absolute neutrophil count (ANC) of Ͻ500/l by day 25 or platelets of Ͻ20 000/l by day 45 after transplant. Target apheresis CD34
+ cell numbers were Ͼ2.5 × 10 6 /kg body weight (bw). Apheresis was started with WBC Ͻ5000/l and PB CD34 + cells of Ͼ40/l using a continuous flow cell separator (Cobe Spectra, Munich, Germany) and a flow rate of 60-100 ml/min. A median of 10 (range, 9-15) liters/single apheresis, and a median total apheresis volume of 12 l (range, 10-20)/PBPC collection was collected. In PB samples, the white blood cell (WBC) count and CD34
+ cells, and in aphereses, WBC, CD34
+ cells and colony forming units (CFU) were determined. Samples from PB and apheresis products were analyzed by dual-color immunfluorescence. 20 
Bone marrow harvesting and cryopreservation
The schedule of the clinical trial consisted of three standard PEC chemotherapy cycles, the PBSC back-up, BM harvest, 12 day culture and high-dose STAMP V treatment as displayed in Figure 1 . The ARS consists of a cell cassette, processor and incubator ( Figure 1 ). BM for the ARS culture was aspirated from the posterior iliac crests under general anesthesia (n = 8) or conscious sedation (n = 2) in the operating room. For these aspirates, 2.5 to 3.0 ml of BM was collected from each BM puncture, comprised of two aspirations at different depths.
Ex vivo culture
The BM mononuclear cells (MNC) were cultured for 12 days in single pass, stromal-based ARS perfusion chambers, using a computer-directed process of gas and medium flow, determined by preclinical studies to maximize hematopoietic cell growth and stromal layer development. Into each of three single-use cassettes 3 × 10 8 MNC, separated using Ficoll-Paque PLUS (Amersham Pharmacia Biotech AB, Uppsala, Sweden), were placed. Oxygen (20%), carbon dioxide (5%), and nitrogen (75%) were continuously exchanged through a gas-permeable, liquid-impermeable membrane covering each culture area (Figure 1 ). The cells were cultured in long-term medium (Life Technologies, Grand Island, NY, USA), consisting of Iscove's modified Dulbecco's medium (IMDM), 10% fetal calf serum (FCS), and 10% horse serum, supplemented with final concentrations of GM-CSF-IL3 fusion protein at 5 ng/ml (PIXY321; Immunex, Seattle, WA, USA), flt3 ligand at 25 ng/ml (Immunex), and erythropoietin (Epo) at 0.1 U/ml (Amgen, Thousand Oaks, CA, USA) for the first five expansions (the first two BM specimens were obtained from normal donors for validation purpose (not transplanted into patients) and three for use after STAMP V chemotherapy). For the following seven expansions, the addition of TPO at 50 ng/ml (CellGenix, Freiburg, Germany) was used. Following high-dose STAMP V (carboplatin, cyclophosphamide, thiotepa) chemotherapy, all patients received 12 day expanded BM cells: in group A (n = 3), Flt3, erythropoietin and PIXY expanded ARS cells, in group B (n = 7) additional TPO and in two of TPO expanded BM patients (group C) also irradiated PBPCs (1 × 10 6 /kg bw) were given. The latter was performed to determine whether irradiated PBPCs as a source of by stander cells can hasten engraftment. Hydrocortisone (final concentration 5 × 10 −6 mol/l, Sigma), l-glutamine Figure 1 Schedule of the clinical trial: three cycles of standard PEC (paclitaxel 175 mg/m 2 , epirubicin 90 mg/m 2 and cyclophosphamide 600 mg/m 2 ) chemotherapy were applied before transplant. Only patients with chemotherapy sensitive disease were included to receive high-dose chemotherapy. The PBSC back-up collection was performed after the 2nd, and the small volume BM harvest after the 3rd PEC cycle. A 12 day culture was performed in the AastromReplicell system (ARS) cell cassette and ex vivo cultured cells were retransfused on day 0 after high-dose STAMP V chemotherapy. The cell processor was used for inoculation and harvest, and an incubator for the 12 day culture period. The ARS performed a computer controlled, stromalbased cell expansion process in disposable cell cassettes as shown, where frequent medium, cytokine and gas exchange allowed BM to grow as nonadherent and adherent cells.
(4 mmol/l), gentamicin sulfate (5 g/ml), and vancomycin (20 g/ml) were added to the media. The cell cassette was maintained at 37°C and the medium reservoir at 4°C. After 12 days, non-adherent cells were collected along with trypsinized adherent cells (0.04% trypsin; Life Technologies), washed four times with 0.5% human albumin in Normosol R, pH 7.4 (Abbott Laboratories, North Chicago, IL, USA) using a COBE 2991 centrifuge (Cobe BCT, Lakewood, CO, USA) and resuspended at a final volume of 250 ml.
In vitro assays of unexpanded and expanded cells
Both before and after expansion, total nucleated cell counts, trypan blue viability assays, CFU and LTC-IC cultures Bone Marrow Transplantation were performed. For clonogenic assays, 1 × 10 5 mononuclear cells were cultured in 0.9% methylcellulose supplemented with IMDM and 30% FCS and stimulated with human Epo (1 U/ml), IL-3 (100 ng/ml) and GM-CSF (100 ng/ml, Genzyme). 20 LTC-IC assays were performed with MNC being seeded in 25 cm 2 tissue flasks (Costar; Corning, Cambridge, MA, USA) at 2 × 10 6 /ml in RPMI supplemented with 12.5% FCS, 12.5% horse serum and 10 −6 m hydrocortisone sodium succinate. 21 After 2 to 3 weeks, the adherent cells were irradiated (15 Gy), harvested, replated in 24 well plates and recharged with non-(day 0) and ex vivo cultured ARS cells (day 12). After 6 weeks with weekly feeding the adherent and non-adherent cells were harvested and plated in methylcellulose as described. CFUs were scored after an additional 14 days in culture.
Before and after expansion, ARS cells were analyzed by flow cytometry using monoclonal antibodies to CD11b, CD3, CD15, CD20, CD34, Thy 1, glycophorin A, CD13, CD61 and CD41 along with isotype controls (Becton Dickinson). The combination of CD11b/CD15 rather than CD33 was used to delineate the mature myeloid population. Because of autofluorescence of stromal cells, routine gating of CD34
+ cells was difficult in the expanded cell product. Therefore, we used the combined CD34
+ , but lineage negative (Lin − /CD34 + ) for T cells, B cells, erythroid cells, and mature myeloid cells (CD3/CD20/CD11b/CD15/Gly-A negative/CD34 + ), as our measure of CD34 content in both the pre-and post-expansion assays.
Routine microbiologic cultures were obtained both before, on day 10 (from the effluent medium line of the cell cassette) and after expansion. The expanded cells were released for transplantation if greater than 1.6 × 10 9 cells were harvested, with a viability of greater than 80%, and with negative microbial cultures.
Tumor cell contamination assays
Samples prior to and after expansion were evaluated with respect to contaminating tumor cells by an immunocytochemical method detecting up to three tumor cells in a background of 1 × 10 6 normal hematopoietic cells as previously described. 22, 23 Briefly, BM cells before and after the ARS culture were attached to poly-L-lysine coated adhesion slides (Marienfeld, Bad Mergentheim, Germany). At least 100 l of the cell suspension was attached on each spot. A total of six spots was analyzed for each preparation (ie 1.5 to 3 × 10 6 total nucleated cells). Antibody staining was performed with anti-cytokeratin and antihuman epithelial cell antigen (HEA 125) antibodies: clone AE1/AE3 (immunoglobulin G1 (IgG1); Boehringer Mannheim, Mannheim, Germany), clone Kl1 (IgG1; Dianova, Hamburg, Germany), and clone HEA 125 (IgG1; Progen, Heidelberg, Germany). An APAAP assay (Dako, Hamburg, Germany) was performed and developed twice to increase chromogen intensity. An irrelevant IgG1 isotype served as a negative control, whereas known tumor contaminated slides were routinely used as positive controls.
High-dose chemotherapy and transplantation of expanded cells
All ARS patients were treated with STAMP V high-dose chemotherapy consisting of carboplatin (800 mg/m 2 ), thiotepa (500 mg/m 2 ), and cyclophosphamide (6000 mg/m 2 ) as described elsewhere. 6, 19, 24, 25 Seventy-two hours after completion of chemotherapy, the unfiltered expanded cells were infused over 60 min. All patients received G-CSF subcutaneously (10 g/kg bw) starting 4 h after cell infusion and continuing until the WBC rose Ͼ1000/l (Figure 1 ). Supportive care consisted of prophylactic fluconazole, platelet transfusions for counts Ͻ20 000/l and red blood cell (RBC) transfusions with a hemoglobin level of Ͻ8 g/dl.
Analysis of engraftment
Primary endpoints were the reliability of the ARS culture system (any ARS failure during the expansion process), toxicities from the infused cells (any adverse events after the infusion of ex vivo expanded ARS cell), time to hematopoietic engraftment, number of platelet and RBC transfusions, days of fever, days of i.v. antibiotics and day of hospital discharge. Engraftment was defined as the first 7 days of ANC Ͼ0.5 × 10 9 /l, and platelets Ͼ20 × 10 9 /l, without need of transfusions.
Comparative analysis with non-expanded PBSCT
The ARS culture and transplant results were compared with non-expanded PBSCT routinely performed in 19 solid tumor patients receiving STAMP V between January 1997 and March 1998 using the post-transplant kinetics as listed above. CD34
+ cells transfused were routinely determined as previously described. 21 There were one male and 18 female patients, the median age was 42 years (range, 23-54) and the median transfused CD34
+ cell dose was 2 × 10 6 /kg bw (range, 1.2-7.2).
Statistics
Comparisons among groups were made with standard statistical tests. Results are expressed as median and range except when stated otherwise. Statistical significance of the data obtained was analyzed by the Wilcoxon rank sum test and the Students' t-test (Statworks, Cricket Software, Philadelphia, PA, USA). The relationship between cell expansion parameters and hematopoietic engraftment was estimated by linear regression and correlation analysis. A P value of less than 0.05 was considered statistically significant.
Results
Apheresis analyses
The median PB WBC counts at PBSC harvest was 24 × 10 
Analyses of expanded BM cells
Twelve BM harvests were performed: two for initial validation purposes and 10 in breast cancer patients. /kg (range, 0.95-5.9), respectively. Total CFU-GM and and CFU-GM/kg were 28.9 × 10 5 (range, 12-60.8) and 3.7 × 10 5 (range, 1.8-6.9), respectively. Median myeloid, erythrocyte, megakaryocytic and other cell subsets before and after expansion are summarized in Figure 2 .
Clinical toxicity and engraftment after ARS BMT
All patients received their expanded cells as planned, with all expansions exceeding minimum culture and viability requirements. All microbiologic tests of the expanded cells were negative and there were no WHO grade 2 or greater toxicities from their infusion. No patient had septicemia before engraftment and there were no grade 2 or greater nonhematopoietic transplant-related toxicities in any patient. The median times to ANC and platelet engraftment and other post-transplant kinetics are outlined in Table 2 . Circulating neutrophils were seen for the first 2 to 3 days after the infusion of expanded cells in most patients, and may have contributed to р2 days of fever post transplant. Of note was that 3/10 patients experienced no fever during the entire transplant course, despite a median time of 16 days to ANC engraftment. The WBC engraftment was identical in all groups, irrespective of whether standard cytokines (group A), the addition of TPO (group B) or TPO plus PBSCs were used (group C). The platelet engraftment was faster with use of TPO (group B) and irradiated PBSC (group C: platelets Ͼ20 000/l day +30 in group A vs +26 in B + C). TPO compared to standard growth factors demonstrated a trend to an increase in Lin − /CD34 + , megakaryocytes (Lin − /CD61 + ; Lin − /CD41 + cells), CFU numbers, faster early hematopoietic engraftment (WBC Ͼ200 and ANC Ͼ500/l), earlier platelet engraftment (platelets Ͼ20 000, 
/CD34
+ and megakaryocytic cell subsets are displayed before (day 0) and after expansion (day 12). 50 000 and 100 000/l), fewer days of antibiotics (AB), less fever and earlier hospital discharge, although, not reaching statistical significance (Table 2) . TPO addition failed to show differences in cell and LTC-IC expansion, myeloid and erythroid cell differentiation, or transfusion requirements. The two patients receiving TPO expanded BM plus irradiated PBSC showed a trend to fewer days of fever (median 1; range, 0-2), AB (11; range, 9-13) and earlier discharge (29; range, 27-31) as compared to group A and B (Table 2) , however this group was too small for statistically significant conclusions.
Factors contributing to engraftment
In one patient (patient No. 10), two instead of three cell cassettes were harvested and reinfused due to a medium and gas perfusion failure in one cell cassette. Table 3 
displays MNC and Lin
− /CD34 + numbers as total numbers and per kg bw in individual ARS and non-expanded CD34 + cell numbers in PBSCT patients. As apparent from Table 3,  MNC and CD34 + cell numbers were reduced by at least 1 log in ARS BMT compared to non-expanded BMT or as transplanted with non-expanded PBSCT.
The ARS patient receiving a low total cell dose of 2.6 × 10 9 MNC and 10.1 × 10 6 Lin − /CD34 + was the latest to engraft with ANC Ͼ500/l and WBC Ͼ1000/l on day +19 and +20, respectively, and the only one who failed to engraft with platelets by day +48, suggesting a dose effect of the reinfused expansion product. Infusion of her backup cryopreserved apheresis cells resulted in platelet ) and engraftment for ANC Ͼ500/l (Figure 3a and b) , WBC Ͼ1000/l (Figure 3c 
Clinical follow-up after ARS BMT
Three of 10 patients received consolidation radiotherapy to the ipsilateral chest wall and axilla, starting around day +60 after transplant. A temporary decrease in platelets, never requiring transfusions, was seen after the radiotherapy was completed. The remission status 6 weeks after transplant was five CR, two PR and three SD. After the median 15 months follow-up, seven out of 10 patients remain alive: four patients in CR, one in SD, two have PD and three with stage IV disease have died 5, 6 and 13 months after transplant due to tumor progression.
Tumor cell contamination assays
Of the 10 pre-expansion samples, three were positive for tumor cells before expansion. The tumor cell-positive preexpansion BM samples contained 1%, 2% and 0.03% tumor cells per total nucleated cells. No tumor cells were detected in 9/10 expanded cell products. In the remaining case, the tumor cell frequency decreased from 2% to 0.025% tumor cells per total nucleated cells. Considering a total cell expansion in this patient of 6.3-fold, total numbers of tumor cells remaining in the expanded cell product were 1 log reduced compared to the initial number present in the preexpansion inoculum. Figure 4 displays the hematopoietic engraftment after reinfusion of ARS cells in 10 ( Figure 4a ) and of unexpanded PBSC in 19 patients (Figure 4b) . Median values of hematopoietic engraftment after ARS transplants and unexpanded
Comparative analysis with non-expanded and ex vivo expanded PBSCT
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PBSCT are depicted in Figure 4c . TPO addition for the ARS BMT displayed a trend to faster WBC engraftment (Figure 4a ), but failed to reach statistical significance due to limited patient numbers. Non-expanded PBSC patients acquired WBC and platelet engraftment on days 11 and 12, received RBC of 3, platelet transfusions of 24 and were discharged on day 19 (Table 4) . While WBC Ͼ1000 l and platelet Ͼ20 000l, days of AB and discharge were faster after non-expanded PBSCT as compared to ARS BMT, finite time to early hematopoietic engraftment reaching WBC Ͼ500l and days of fever were comparable in both groups ( Figure 4c and Table 4 ). Transfusion requirements, although higher in the ARS group, did not demonstrate statistically significant differences due to increased numbers in some PBSC patients (Table 4) .
Discussion
Using a stromal-based, continuous perfusion system for BM expansion, we have achieved engraftment in patients after high-dose chemotherapy with a thiotepa-based regimen, 6, 24, 25 starting from a median unprimed BM volume of only 97.8 ml. Although we cannot completely rule out a contribution from endogenous stem cells, previous work has demonstrated complete myeloablation after STAMP V chemotherapy and no endogenous hematopoietic engraftment without reinfusion of back-up cells, 6, 19, 24, 25 thus making this possibility unlikely. Despite our infusion of approximately 1 log fewer ARS cells, engraftment for neutrophils and platelets was similar to that of a typical 1000 to 1500 ml autologous BM transplant. 26, 27 As recently noted for BM or PBSC transplants, 25, 28, 29 ARS engraftment for both neutrophils and platelets was directly correlated to the CD34 cell dose transplanted. One patient, who received the graft from two instead of three cell cassettes experienced prolonged thrombocytopenia, thus confirming (1) the myeloablative effect of the STAMP V regimen beyond 40 days post stem cell reinfusion; and (2) the dose effect of the expanded cell product, leading to rapid, or with infusion of low MNC and CD34 + cells, delayed engraftment. Compared to previous ex vivo generated PBSCT, 4 engraftment after ARS transplants was sustained. This suggests a loss of primitive PBSC, at least with use of beyond 7 days and without stromal support cultured PBSC (with no hematopoietic rescue after myeloablation when used as the only transplant source). 4 Nevertheless, others have shown a shortening of neutropenia when expanded CD34 + cells are infused along with standard PBSC, supporting the concept Bone Marrow Transplantation of engraftment with use of expanded, in concert with unexpanded grafts. 26, 27 Preliminary experience from our ongoing phase II study also suggests that shorter expansion periods, frequent medium exchange and Flt-3, SCF, TPO and low doses of IL-3 are of value for sustained engraftment after myeloablation (C v Kalle, personal communication).
The most rapid engraftment after ARS transplantation was observed in patients receiving у3 × 10 5 /kg Lin − /CD34 + cells. Possibly, stromal cells 30 that were infused with the expanded BM cells, promoted engraftment of a lower stem cell dose. Expanded stromal progenitor cells (as measured by the CFU-F assay 31 ) have been shown to substantially increase during the 12-day culture period which have been demonstrated to be important in facilitating engraftment. 32 Stromal cell damage and telomere loss exist before, [33] [34] [35] [36] [37] and after high-dose therapy, 38-40 possibly due to a reduction of vascular cell adhesion molecules on BM stromal cells after strong proliferative stress and cellular senescence. Stromal cell contact appears critical for primitive hematopoietic cell expansion ex vivo, 26, 27 which has been shown to shorten engraftment when used as expanded mesenchymal cells along with non-expanded stem cells. 41 Although expansion in the perfusion bioreactors led to maintenance of the primitive stem cell pool as measured by LTC-IC and Lin − /CD34 + populations, this was less than that seen in preclinical experiments. [13] [14] [15] [16] [17] [18] Reasons for this observation may include that initial experiments used BM from healthy volunteers; the cytokines used in the earlier studies were GM-CSF, IL-3, Epo, and SCF, and recent data suggest an advantage of using Flt-3, SCF, IL-6 and TPO in conjunction with stromal or mesenchymal stem cell support. [7] [8] [9] [10] [11] [12] Our results with a correlation of a Lin − /CD34 + cell dose of Ͼ3 × 10 5 /kg and rapid hematopoietic engraftment suggest that the improvement of CD34 expansion may yield faster engraftment times. This may be achieved by the use of Flt-3, SCF, IL-6, TPO, and possibly novel cytokines, higher BM doses collected after a short course of G-CSF, the combination of ex vivo expanded cells plus (nonirradiated) mobilized stem cells or other cell subsets. 19 Although the ARS technology used here had a lesser degree of total cell expansion, [8] [9] [10] [11] [12] there appeared to be a maintenance, or in some cases an expansion of primitive stem cells. In addition, with constant medium, cytokine and gas exchange in the closed bioreactor system, the risk of infectious contamination was minimized. With use of TPO and irradiated PBSC, early hematopoietic engraftment was enhanced, although significant improvements on expansion and engraftment kinetics were not yet observed, most likely due to limited patient numbers. Nevertheless, it was of interest that TPO compared to standard growth factors demonstrated a trend to an increase in Lin − /CD34 + and megakaryocytes, CFU numbers, fewer days of fever, antibiotics and earlier hospital discharge. The additional use of nonexpanded irradiated PBSC displayed fewer days of fever, antibiotics and earlier discharge. Moreover, our finding of few febrile days during neutropenia was impressive in all patients and seemed due to circulating neutrophils, resulting from the infusion of large numbers of committed myeloid progenitors.
As a significant number of patients with solid tumors have clonogenic tumor cells found in their marrow or PBSC transplants, a smaller starting inoculum, as the 1 log reduced marrow in this study and passive purging during the ex vivo culture should reduce the risk of tumor cell infusion during transplantation. Although definite conclusions about passive purging cannot be made based on our and previous data, 18 it was of interest that we found no or reduced tumor cell numbers post expansion. Therefore, considering the smaller starting inoculum and passive purging effect, a 2 to 4 log tumor cell reduction for an expanded transplant vs a typical unexpanded autologous BM or PBSC transplant could be expected.
Based on this investigation, we show that ex vivo expansion of a 1 log reduced, non-G-CSF-mobilized BM aliquot allowed hematopoietic engraftment after myeloablation, that early WBC engraftment was similar to unexpanded PBSCT, and sufficient ARS cells can be generated. This technology appears useful in patients with a small starting stem cell aliquot or in those who poorly mobilize stem cells with current methodologies. (It is noteworthy that stem cell growth in perfusion bioreactors is independent of stem cell mobilization, with expected expansions seen in patients who are poor mobilizers 42 ). Nevertheless, since telomere shortening in culture has been observed due to extensive proliferation (which is not fully compensated by telomerase levels 10, 34 ) and since telomere loss may be reduced by transplanting large cell numbers, 43 ,44 a further increase in transplanted ARS cells may reduce or completely prevent a telomeric decline and add to an even prompter neutrophil and platelet engraftment. In this light, it will be intriguing to analyze maximum numbers of ARS cells, alone or in concert with PBSC or other cell subsets in subsequent studies.
